Inhibrx, Inc. (INBX)
NASDAQ: INBX · IEX Real-Time Price · USD
34.14
-0.05 (-0.15%)
At close: May 24, 2024, 4:00 PM
35.00
+0.86 (2.52%)
After-hours: May 24, 2024, 4:48 PM EDT

Company Description

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates.

The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications.

The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company.

Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Inhibrx, Inc.
Inhibrx logo
Country United States
Founded 2010
IPO Date Aug 19, 2020
Industry Biotechnology
Sector Healthcare
Employees 172
CEO Mark Paul Lappe

Contact Details

Address:
11025 N. Torrey Pines Road, Suite 200
La Jolla, California 92037
United States
Phone (858) 795-4220
Website inhibrx.com

Stock Details

Ticker Symbol INBX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001739614
CUSIP Number 45720L107
ISIN Number US45720L1070
Employer ID 82-4257312
SIC Code 2836

Key Executives

Name Position
Mark Paul Lappe Founder, Chairman, President and Chief Executive Officer
Dr. Brendan P. Eckelman Ph.D. Founder and Chief Scientific Officer
Kelly Devine Deck B.S., CPA, M.S. Executive Vice President and Chief Financial Officer
Quinn L. Deveraux Founder
Dr. Ashraf Amanullah Executive Vice President and Chief Technical Operations Officer
Leah Pollema J.D. Vice President, Corporate Secretary and General Counsel
Dr. Charbel Helaihel Pharm.D. Vice President of Marketing and Commercial Planning
Jeffrey J. Jensen Executive Vice President and Chief Clinical Operations Officer
David Matly M.B.A. Executive Vice President and Chief Commercial and Business Development Officer
Dr. Carlos Bais Ph.D. Executive Vice President of Translational Sciences

Latest SEC Filings

Date Type Title
May 24, 2024 3 Initial statement of beneficial ownership of securities
May 24, 2024 8-K Current Report
May 22, 2024 144 Filing
May 21, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 17, 2024 8-K Current Report
May 17, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 9, 2024 8-K Current Report
May 9, 2024 10-Q Quarterly Report
May 8, 2024 8-K Current Report
May 6, 2024 144 Filing